Foresite Capital
Dr. Michael Rome joined Foresite Capital in 2016 and co-leads the therapeutics investing practice. Michael is a board director at Kinnate Biopharma, Pharvaris, and Remix Therapeutics, with board observer roles (past and present) at Turning Point Therapeutics, Maze Therapeutics, PACT Pharma, and Nurix Therapeutics. Michael served as Vice President for Foresite Development Corporation (FSDC) and has led investments in several public companies across the portfolio. Prior to Foresite Capital, he was an analyst at DAFNA Capital Management, covering and formulating investment ideas for small/mid-cap biotech companies.
This person is not in any offices
Foresite Capital
2 followers
Foresite Capital is a multi-stage healthcare and life sciences investment firm with ~ $4B in assets under management. The firm aims to address areas of great unmet need by funding promising healthcare and life sciences businesses at all stages of their life cycles.